- Onconetix, Inc. entered into a **Registration Rights Agreement** on **October 1, 2025**, with buyers in connection with a Securities Purchase Agreement.  **[1782107_0001213900-25-095847_ea025986001ex10-2_onconetix.htm:0]** 
- This agreement grants buyers certain **registration rights** under the 1933 Act for the resale of **Series E Convertible Preferred Stock** and **Warrants**, which are convertible into or exercisable for shares of the Company's common stock.  **[1782107_0001213900-25-095847_ea025986001ex10-2_onconetix.htm:0]** 
- As of the date of the document, Onconetix, Inc. has **1,550,132 shares of Common Stock issued and outstanding** and **16,350 shares of Preferred Stock issued and outstanding** (comprising 7 Series C and 16,343 Series D shares).  **[1782107_0001213900-25-095847_ea025986001ex10-1_onconetix.htm:17]** 
- The agreement outlines "Triggering Events," including the failure to pay indebtedness exceeding **$500,000** or if any Preferred Shares remain outstanding on or after **April 2, 2027**.  **[1782107_0001213900-25-095847_ea0259860-8k_onconetix.htm:5]** **[1782107_0001213900-25-095847_ea025986001ex3-1_onconetix.htm:18]**

Onconetix, Inc. Enters Registration Rights Agreement for Series E Preferred Stock and Warrants

- On September 22, 2025, Onconetix, Inc. completed a private placement financing of approximately **$12.9 million** through the issuance of Series D Convertible Preferred Stock and Warrants.  **[1782107_0001213900-25-091966_ea025883001ex99-1_onconetix.htm:0]**  Approximately **$9.3 million** of this was paid in cash, with the balance used to offset certain amounts owed to investors.  **[1782107_0001213900-25-091966_ea025883001ex99-1_onconetix.htm:0]** 
- The company settled an **$8.8 million debt** to Veru, Inc., by paying **$6.3 million** in cash from the financing proceeds and converting the remaining **$2.5 million** of debt into Series D Preferred Stock and warrants.  **[1782107_0001213900-25-091966_ea025883001ex99-1_onconetix.htm:0]** 
- Onconetix and Ocuvex Therapeutics, Inc. mutually terminated their previously announced definitive merger agreement, which was dated July 16, 2025.  **[1782107_0001213900-25-091966_ea025883001ex99-1_onconetix.htm:0]** **[1782107_0001213900-25-091966_ea025883001ex99-2_onconetix.htm:0]** 
- The remaining net cash proceeds from the financing are intended to cover costs associated with the Ocuvex merger termination, and for working capital and general corporate purposes.  **[1782107_0001213900-25-091966_ea025883001ex99-1_onconetix.htm:0]**

Onconetix Announces $12.9 Million Private Placement, Debt Settlement, and Merger Termination

- On **September 17, 2025**, Onconetix, Inc.'s wholly-owned subsidiary, **Proteomedix AG**, entered into a licensing agreement with **Immunovia AB**.  **[1782107_0001213900-25-089845_ea025819601ex10-1_onconetix.htm:0]** **[1782107_0001213900-25-089845_ea025819601ex99-1_onconetix.htm:0]** **[1782107_0001213900-25-089845_ea0258196-8k_onconetix.htm:1]** 
- Under the agreement, Proteomedix will provide Immunovia with **master cells** for antibodies related to three biomarkers for the **PancreaSure** test and a license for **key intellectual property** for manufacturing reagents.  **[1782107_0001213900-25-089845_ea025819601ex99-1_onconetix.htm:0]** **[1782107_0001213900-25-089845_ea0258196-8k_onconetix.htm:1]** 
- Immunovia will make payments totaling **$700,000** to Proteomedix in **2025 and 2026**, including two **$300,000** payments due on **September 30, 2025**, and **March 31, 2026**, and a **$100,000** payment for materials.  **[1782107_0001213900-25-089845_ea025819601ex99-1_onconetix.htm:0]** **[1782107_0001213900-25-089845_ea0258196-8k_onconetix.htm:1]** **[1782107_0001213900-25-089845_ea025819601ex10-1_onconetix.htm:6]** 
- Additionally, Immunovia will pay a **3% royalty** on net sales of PancreaSure and other products incorporating the licensed intellectual property from **January 1, 2026, through December 31, 2032**.  **[1782107_0001213900-25-089845_ea025819601ex99-1_onconetix.htm:0]** **[1782107_0001213900-25-089845_ea0258196-8k_onconetix.htm:1]** **[1782107_0001213900-25-089845_ea025819601ex10-1_onconetix.htm:6]**

Onconetix (ONCO)